FlAIR Trial 2018 update


This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL). The CLLSA supports this research.

The Flair Trial researchers think that ibrutinib with rituximab, or venetoclax, might work well for people with CLL who haven’t yet had treatment. To find this out they want to compare:

fludarabine, cyclophosphamide and rituximab (FCR)

ibrutinib and rituximab (This arm is of the trial is now closed)

ibrutinib and venetoclax


The aims of this trial are to find out:

which treatment is the best for people with CLL that hasn't been treated  

how safe these treatments are

what are the side effects of these treatments

Read the full article here.This includes a list of all the UK centres running the Flair trial as well as a link to a map showing these centres.

Thanks to Cancer Research UK for the image